1. Wang H, Guo P, Sun H, Wang H, Yang Q, Chen M, et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrob Agents Chemother 2007; 51(11): 4022-8. 2. Fournier PE, Richet H, Weinstein RA. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42(5): 692-9. 3. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005; 11(1): 22-9. 4. Cambray G, Guerout AM, Mazel D. Integrons. Annu Rev Genet 2010; 44: 141-66. 5. Qi L, Li H, Zhang C, Liang B, Li J, Wang L, et al. Relationship between Antibiotic Resistance, Biofilm Formation, and Biofilm-Specific Resistance in Acinetobacter baumannii. Front Microbiol 2016; 7: 483. 6. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53(8): 3430. 7. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012; 54(12): 1720-6. 8. Akinci E, Vahaboglu H. Minor extended-spectrum β-lactamases. Expert Rev Anti Infect Ther 2010; 8(11): 1251-8. 9. Clinical and Laboratory Standards Institute. M100-S23 Performance Standards for antimicrobial susceptibility testing 23th information supplement. 2013. 10. Mostofi S, Mirnejad R, Masjedian F. Multi-drug resistance in Acinetobacter baumannii strains isolated from clinical specimens from three hospitals in Tehran-Iran. African J Microbiol Res 2011; 5(21): 3579-82. 11. Safari M, Saidijam M, Bahador A, Jafari R, Alikhani MY. High Prevalence of Multidrug Resistance and Metallo-beta-lactamase (MβL) producing Acinetobacter Baumannii Isolated from Patients in ICU Wards, Hamadan, Iran. J Res Health Sci 2013; 13(2): 162-7. 12. Mohajeri P, Farahani A, Feizabadi MM, Ketabi H, Abiri R, Najafi F. Antimicrobial Susceptibility Profiling and Genomic Diversity of Acinetobacter baumannii isolates: A study in western Iran. Iran J Microbiol 2013; 5(3): 195. 13. Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, et al. Antimicrobial susceptibility patterns and distribution of blaOXA genes among Acinetobacter spp. isolated from patients at Tehran hospitals. Jpn J Infect Dis 2008; 61(4): 274-8. 14. Boromand M, Akyani M, Sheikhvatan R, Hekmat Yazdi S, Saboorian R, Hashemi SH, et al. Evaluation of antimicrobial resistance of Acinetobacter baumannii to Imipenem, Ciprofloxacinand Ceftazidim using E test. Iran J Publ Health 2009; 2(38): 130-3. 15. Khosrou SN, Sharifi M. Isolation of carbapenem resistant acinetobacter baumannii (crab) strains from patients and equipments of intensive care units (icus) at qazvin between 2005-2006. J Med Microbiol 2007; 1(3): 33-8. 16. Van Looveren M, Goossens H, ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10(8): 684–704. 17. Farajnia S, Azhari F, Alikhani MY, Hosseini MK, Peymani A, Sohrabi N. Prevalence of PER and VEB Type Extended Spectrum Betalactamases among Multidrug Resistant Acinetobacter baumannii Isolates in North-West of Iran. Iran J Publ Health 2013; 16(6): 751-5. 18. Pasterán F, Rapoport M, Petroni A, Faccone D, Corso A, Galas M, et al. Emergence of PER-2 and VEB-1a in Acinetobacter baumannii strains in the Americas. Antimicrob Agents Chemother 2006; 50(9): 3222-4. 19. Naas T, Bogaerts P, Bauraing C, Degheldre Y, Glupczynski Y, Nordmann P. Emergence of PER and VEB extended-spectrum β-lactamases in Acinetobacter baumannii in Belgium. Antimicrob Agents Chemother 2006; 58(1): 178-82. 20. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 2003; 41(8): 3542-7. 21. Carbonne A, Naas T, Blanckaert K, Couzigou C, Cattoen C, Chagnon JL, et al. Investigation of a nosocomial outbreak of extended-spectrum beta-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a hospital setting. J Hosp Infect 2005; 60(1): 14-8. 22. de Vries J, Wackernagel W. Integration of foreign DNA during natural transformation of Acinetobacter sp. by homology-facilitated illegitimate recombination. Proc Natl Acad Sci U S A 2002; 99(4): 2094-9. 23. Van Dessel H, Dijkshoorn L, Van der Reijden T, Bakker N, Paauw A, van den Broek P, et al. Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. Res Microbiol 2004; 155(2): 105-12. 24. Marqué S, Poirel L, Héritier C, Brisse S, Blasco MD, Filip R, et al. Regional occurrence of plasmid-mediated carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter spp. in Europe. J Clin Microbiol 2005; 43(9): 4885-8. 25. Turton JF, Kaufmann ME, Warner M, Coelho J, Dijkshoorn L, van der Reijden T, et al. A prevalent, multiresistant clone of Acinetobacter baumannii in Southeast England. J Hosp Infect 2004; 58(3): 170-9. 26. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol 2005; 43(9): 4826-9.
|